Randomised clinical trial: the effects of pregabalin vs placebo on functional dyspepsia.

Abstract

Currently, central neuromodulators are among the therapeutic options for the treatment of functional dyspepsia (FD). Pregabalin, a gabapentinoid, is a neuromodulator that could potentially improve visceral hypersensitivity in FD patients. To assess the efficacy and safety of pregabalin for the treatment of FD METHODS: We performed a randomised placebo-controlled study including FD patients who did not respond to proton pump inhibitors. Patients were randomly assigned to receive pregabalin (75mg daily) or placebo for 8weeks. The primary outcome was an adequate relief response rate. The secondary outcomes were improvement in quality of life, pain scores in divided categories, and safety profile. Of 72 patients enrolled, 34 received pregabalin and 38 received placebo. The self-reported adequate relief rates in the pregabalin and placebo groups were 70.6% and 42.1% at week 4 (P=0.02), and 70.6% and 44.7% at week 8 (P=0.03), respectively. The reduction in global symptoms in the pregabalin and placebo groups were 11.7±10.6 and 3.7±8.9 points at week 4 (P<0.01) and 15.1±12.2 and 8.0±10.2 points at week 8 (P=0.01), respectively. Pregabalin improved the overall quality of life (P=0.03). The most common adverse event with pregabalin was dizziness, occurring in 51.6% of patients. Pregabalin led to significant alleviation of dyspeptic symptoms, especially in patients with predominant epigastric pain . Thaiclinicaltrials.org #TCTR20200404002.